Scinai Immunotherapeutics (SCNI) Competitors $2.94 +0.04 (+1.21%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. SNSE, BLRX, QNTM, TLPH, PHXM, INDP, PMCB, APLM, TXMD, and GELSShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Sensei Biotherapeutics (SNSE), BioLineRx (BLRX), Quantum Biopharma (QNTM), Talphera (TLPH), PHAXIAM Therapeutics (PHXM), Indaptus Therapeutics (INDP), PharmaCyte Biotech (PMCB), Apollomics (APLM), TherapeuticsMD (TXMD), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Sensei Biotherapeutics BioLineRx Quantum Biopharma Talphera PHAXIAM Therapeutics Indaptus Therapeutics PharmaCyte Biotech Apollomics TherapeuticsMD Gelteq Scinai Immunotherapeutics (NASDAQ:SCNI) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership. Does the MarketBeat Community believe in SCNI or SNSE? Sensei Biotherapeutics received 30 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformScinai ImmunotherapeuticsN/AN/ASensei BiotherapeuticsOutperform Votes3081.08% Underperform Votes718.92% Is SCNI or SNSE more profitable? Scinai Immunotherapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Scinai ImmunotherapeuticsN/A N/A -30.48% Sensei Biotherapeutics N/A -53.86%-46.91% Do analysts recommend SCNI or SNSE? Sensei Biotherapeutics has a consensus target price of $4.25, indicating a potential upside of 551.84%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SCNI or SNSE? In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 7 mentions for Sensei Biotherapeutics and 6 mentions for Scinai Immunotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.96 beat Scinai Immunotherapeutics' score of 0.13 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in SCNI or SNSE? 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 22.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, SCNI or SNSE? Scinai Immunotherapeutics has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Which has stronger valuation and earnings, SCNI or SNSE? Scinai Immunotherapeutics has higher revenue and earnings than Sensei Biotherapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScinai Immunotherapeutics$452K5.54-$6.50M-$239.17-0.01Sensei BiotherapeuticsN/AN/A-$34.10M-$1.19-0.55 SummaryScinai Immunotherapeutics beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.51M$3.02B$5.64B$8.00BDividend YieldN/A1.56%4.57%4.01%P/E Ratio-0.0129.1523.1618.89Price / Sales5.54433.49384.1492.98Price / CashN/A168.6838.1634.64Price / Book-0.303.906.904.30Net Income-$6.50M-$71.95M$3.20B$247.06M7 Day Performance-14.46%-4.32%-1.69%-0.62%1 Month Performance-17.09%-10.86%2.68%-4.26%1 Year Performance-43.45%-27.46%10.20%0.61% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics0.6488 of 5 stars$2.94+1.2%N/A-42.0%$2.51M$452,000.00-0.0120Short Interest ↑News CoverageSNSESensei Biotherapeutics4.6566 of 5 stars$0.45-2.7%$4.33+858.7%-60.5%$11.44MN/A-0.3840Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageBLRXBioLineRx2.6476 of 5 stars$3.32-3.1%$360.00+10,759.7%-92.8%$11.04M$21.99M-0.3840Upcoming EarningsQNTMQuantum BiopharmaN/A$5.76+3.8%N/AN/A$11.03MN/A-0.37N/AUpcoming EarningsNews CoverageGap UpTLPHTalphera2.1637 of 5 stars$0.64-0.6%$4.33+582.4%-43.6%$10.81M$281,000.00-0.9219Short Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049INDPIndaptus Therapeutics3.6246 of 5 stars$0.73+9.9%$8.50+1,070.8%-73.9%$10.48MN/A-0.426High Trading VolumePMCBPharmaCyte Biotech1.3988 of 5 stars$1.52-3.2%N/A-43.4%$10.43MN/A2.874Short Interest ↑Positive NewsAPLMApollomics2.6087 of 5 stars$9.57+0.7%$200.00+1,991.0%-86.1%$10.40M$1.22M0.0045Short Interest ↓News CoverageGap UpTXMDTherapeuticsMD0.9189 of 5 stars$0.89+2.3%N/A-53.3%$10.19M$1.60M0.00420Upcoming EarningsShort Interest ↓News CoverageGELSGelteqN/A$1.05+0.5%N/AN/A$9.91MN/A0.00N/A Remove Ads Related Companies and Tools Related Companies Sensei Biotherapeutics Alternatives BioLineRx Alternatives Quantum Biopharma Alternatives Talphera Alternatives PHAXIAM Therapeutics Alternatives Indaptus Therapeutics Alternatives PharmaCyte Biotech Alternatives Apollomics Alternatives TherapeuticsMD Alternatives Gelteq Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
